Sign inJoin waitlistJoin the waitlist

Richard O’Reilly

Physician · New York Presbyterian Hospital

Credentials: · ·

History

New York Presbyterian Hospital
Present

Pediatrics

Research

Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
Nature · 1999 · 757 citations
Transplantation outcomes for severe combined immunodeficiency, 2000-2009
New England Journal of Medicine · 2014 · 540 citations
Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells
Case report · Blood · 1983 · Last of 9 authors · 482 citations

NK
Nancy Kernan
90 papers · 4 as a fellow
TS
Trudy Small
59 papers
Susan Prockop
58 papers
EP
Esperanza Papadopoulos
56 papers
FB
Farid Boulad
50 papers
AJ
Ann Jakubowski
49 papers
HC
Hugo Castro-Malaspina
48 papers
MP
Miguel-Angel Perales
48 papers
NK
Neena Kapoor
44 papers
SG
Sergio Giralt
44 papers
Alfred Gillio
41 papers
AS
Andromachi Scaradavou
35 papers

Grants

Immunobiology of Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute · P01
Contact PI · $76.9M · Sloan-Kettering Inst Can Research
1978–2025
Primary Immune Deficiency Treatment Consortium
National Institute of Allergy and Infectious Diseases · U54
Project lead · $395.5K · University of California, San Francisco
2009–2014
EBV Specific T-Cells from 3rd Party Donors for Treatment of EBV-Associated Malign
National Cancer Institute · R21
Contact PI · $755.2K · Sloan-Kettering Inst Can Research
2011–2013
Genetic Approaches to Cancer Immunotherapy
National Cancer Institute · P01
Project lead · $2.7M · Sloan-Kettering Inst Can Research
1997–2013

Clinical trials

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Principal investigator · Terminated
Memorial Sloan Kettering Cancer Center
2012–2017
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2010–2021
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2007–2021
Patients Treated for SCID (1968-Present)
Study chair · Unknown
National Institute of Allergy and Infectious Diseases (NIAID)
2011–2023